Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS)... Show more
VERU is expected to report earnings to fall 88.66% to -5 cents per share on December 01
Q3'25
Est.
$-0.06
Q2'25
Missed
by $0.45
Q1'25
Beat
by $0.01
Q4'24
Beat
by $0.02
Q3'24
Beat
by $0.01
The last earnings report on August 12 showed earnings per share of -50 cents, missing the estimate of -5 cents. With 216.76K shares outstanding, the current market capitalization sits at 52.59M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. VERU showed earnings on August 12, 2025. You can read more about the earnings report here.